**Figure 2.** **Relationship between TMPRSS2 expression and clinicopathological parameters of lung cancer patients.** TMPRSS2 expression was assessed in (**A**) male and female LUAD (normal, *n* = 59; male, *n* = 238; female, *n* = 276) and LUSC (normal, *n* = 52; male, *n* = 366; female, *n* = 128) patients, (**B**) patients with different stages of LUAD (normal, *n* = 59; stage 1, *n* = 277; stage 2, *n* = 125, stage 3, *n* = 85; stage 4, *n* = 28) and LUSC (normal, *n* = 52; stage 1, *n* = 243; stage 2, *n* = 157, stage 3, *n* = 85; stage 4, *n* = 7), (**C**) patients with different nodal metastasis statuses of LUAD (normal, *n* = 59; N0, *n* = 331; N1, *n* = 96, N2, *n* = 74; N3, *n* = 2) and LUSC (normal, *n* = 52; N0, *n* = 320; N1, *n* = 131, N2, *n* = 40; N3, *n* = 5). ^{*}*p* < 0.05, ^{**}*p* < 0.01, ^{***}*p* < 0.001.